Structure Therapeutics (NASDAQ:GPCR) Rating Reiterated by Cantor Fitzgerald

Structure Therapeutics (NASDAQ:GPCR)‘s stock had its “overweight” rating reissued by stock analysts at Cantor Fitzgerald in a research report issued on Friday, Benzinga reports. They currently have a $65.00 target price on the stock. Cantor Fitzgerald’s price objective suggests a potential upside of 65.44% from the stock’s current price.

Separately, Lifesci Capital reiterated an “outperform” rating on shares of Structure Therapeutics in a research report on Tuesday, February 27th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $85.71.

Structure Therapeutics Stock Up 0.8 %

Shares of GPCR opened at $39.29 on Friday. The company has a 50 day moving average price of $39.34 and a 200-day moving average price of $46.82. Structure Therapeutics has a fifty-two week low of $21.79 and a fifty-two week high of $75.02.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings data on Friday, March 8th. The company reported ($0.17) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.04. As a group, sell-side analysts anticipate that Structure Therapeutics will post -0.98 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Structure Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in GPCR. Wellington Management Group LLP boosted its stake in Structure Therapeutics by 404.0% in the 4th quarter. Wellington Management Group LLP now owns 4,372,326 shares of the company’s stock worth $178,216,000 after buying an additional 3,504,747 shares during the last quarter. Adage Capital Partners GP L.L.C. boosted its stake in Structure Therapeutics by 835.5% in the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 1,799,923 shares of the company’s stock worth $90,752,000 after buying an additional 1,607,525 shares during the last quarter. Avoro Capital Advisors LLC boosted its stake in Structure Therapeutics by 133.3% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,333,333 shares of the company’s stock worth $95,107,000 after buying an additional 1,333,333 shares during the last quarter. Federated Hermes Inc. boosted its stake in Structure Therapeutics by 104.2% in the 4th quarter. Federated Hermes Inc. now owns 2,267,206 shares of the company’s stock worth $92,411,000 after buying an additional 1,157,006 shares during the last quarter. Finally, Capital International Investors acquired a new stake in Structure Therapeutics in the 4th quarter worth about $34,647,000. 91.78% of the stock is owned by institutional investors and hedge funds.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.